Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ana Bernhard"'
Autor:
Anne Månsson Kvarnhammar, Juha Punnonen, Enping Hong, Diana Reich, Karan Uppal, Kathy Bang, David B Rosen, Burkhardt Laufer, Thomas Knappe, Jens Jakob Karlsson, Yu-Chi Lee, Dhruv Thakar, Luis Alejandro Zúñiga, Simran Singh Sabharwal, Janne Damm Olling, Kristian Kjaergaard, Thomas Kurpiers, Meike Schnabel, Philipp Glock, Joachim Zettler, Mathias Krusch, Ana Bernhard, Stefan Heinig, Valentino Konjik, Thomas Wegge, Yvonne Hehn, Steffen Killian, Laura Viet, Josefine Runz, Frank Faltinger, Mohammad Tabrizi, Kristin Laura Abel, Vibeke Miller Breinholt, Stina M Singel, Kennett Sprogøe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 7 (2022)
Background Recombinant interleukin-2 (IL-2, aldesleukin) is an approved cancer immunotherapy but causes severe toxicities including cytokine storm and vascular leak syndrome (VLS). IL-2 promotes antitumor function of IL-2Rβ/γ+ natural killer (NK) c
Externí odkaz:
https://doaj.org/article/c5975468cd0f4febb405f737118e732f
Autor:
C.E. Rasmussen, Frank Faltinger, Per Holse Mygind, Ana Bernhard, Mads Kjelgaard-Hansen, Joachim Zettler, Vibeke Miller Breinholt, Ulrich Hersel
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 370(3)
TransCon CNP is a C-type natriuretic peptide (CNP-38) conjugated via a cleavable linker to a polyethylene glycol carrier molecule, designed to provide sustained systemic CNP levels upon weekly subcutaneous administration. TransCon CNP is in clinical
Autor:
Valentino Konjik, Thomas Wegge, Vibeke Miller Breinholt, Meike Schnabel, Thomas Knappe, Burkhardt Laufer, Kennett Sprogøe, Joachim Zettler, Mohammad Tabrizi, Rosen David B, Juha Punnonen, Ana Bernhard, Stefan Heinig, Mathias Krusch, Diana Begaliew
Publikováno v:
Cancer Research. 80:4507-4507
Background: Recombinant Interleukin-2 (IL-2, aldesleukin) is an approved immunotherapy for metastatic melanoma and renal cell carcinoma. However, treatment with IL-2 can induce severe side effects, such as vascular leak syndrome (VLS) and eosinophili